3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Fluorouracil
56
Specimen Handling
51
Oxaliplatin
49
Leucovorin
46
Magnetic Resonance Spectroscopy
45
Bevacizumab
43
Gemcitabine
39
Irinotecan
30
Cetuximab
27
Nivolumab
25
130-nm albumin-bound paclitaxel
25
Cisplatin
24
Biopsy
24
pembrolizumab
22
Paclitaxel
22
Capecitabine
19
atezolizumab
18
durvalumab
14
Taxes
14
Folfox protocol
14
Carboplatin
13
X-Rays
12
Radiotherapy
12
Cyclophosphamide
12
fludarabine
11
dehydroftorafur
10
Radiation
10
Albumin-Bound Paclitaxel
10
Surgical Procedures, Operative
9
Immunoglobulin G
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
entrectinib
×
Gastrointestinal
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA